Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
about
Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.
P2860
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatocyte growth factor reduc ...... cells harboring wild-type EGFR
@en
Hepatocyte growth factor reduc ...... ells harboring wild-type EGFR.
@nl
type
label
Hepatocyte growth factor reduc ...... cells harboring wild-type EGFR
@en
Hepatocyte growth factor reduc ...... ells harboring wild-type EGFR.
@nl
prefLabel
Hepatocyte growth factor reduc ...... cells harboring wild-type EGFR
@en
Hepatocyte growth factor reduc ...... ells harboring wild-type EGFR.
@nl
P2093
P2860
P356
P1433
P1476
Hepatocyte growth factor reduc ...... cells harboring wild-type EGFR
@en
P2093
P2860
P304
16273-16281
P356
10.18632/ONCOTARGET.7586
P407
P577
2016-02-22T00:00:00Z